tiqueside: reduces intestinal cholesterol absorption with little change in HDL-cholesterol levels & without interfering with enterohepatic bile acid recirculation ; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 146160339 |
| MeSH ID | M0215319 |
| Synonym |
|---|
| tiqueside |
| cp 88818; tigogenin cellobioside; tigogenyl beta-cellobioside |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Given the known hypocholesterolemic and antiatherosclerotic properties of some steroid glycosides, we synthesized a series of sterol derivatives by coupling some phytosterols known to interact with sterol absorption and also to be poorly absorbed to a cationic group." | ( Selection of cholesterol absorption inhibitors devoid of secondary intestinal effects. Abou el Fadil, F; Boubia, B; Descroix-Vagne, M; Guffroy, C; Marquet, F; Pansu, D, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||